Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SSTR4 | P31391 | 6/20 | 0.41 |
| ▸ | PLK1 | P53350 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | REN | P00797 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5948132 | 0.81 | SSTR4 (0.41) | SSTR4 | |
| SCHEMBL6937389 | 0.81 | SSTR4 (0.43) | SSTR4 | |
| SCHEMBL21484361 | 0.81 | SSTR4 (0.41) | SSTR4 | |
| SCHEMBL3742282 | 0.80 | SSTR4 (0.45) | SSTR4REN | |
| SCHEMBL8292968 | 0.80 | SSTR4 (0.45) | SSTR4REN | |
| SCHEMBL28109125 | 0.80 | REN (0.47) | ALDH1A1MAPK1SSTR4REN | |
| SCHEMBL6798494 | 0.80 | HPGD (0.42) | ALDH1A1SMN1; SMN2SSTR4REN | |
| Hydrochloric Acid SCHEMBL4031709 | 0.79 | SSTR4 (0.44) | SSTR4REN | |
| SCHEMBL15090452 | 0.79 | SSTR4 (0.41) | SSTR4 | |
| SCHEMBL715727 | 0.79 | ALDH1A1 (0.47) | ALDH1A1TSHRMAPK1SMN1; SMN2SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117641746-A | Transparent conductive substrate and double-sided photolithography method using same | 杜邦电子公司 | 2024-03-01 | — | — | CN | disclosed |
| US-7776884-B2 | Cyclic derivatives as modulators of chemokine receptors activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-17 | — | — | US | disclosed |
| US-7087604-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-08-08 | — | — | US | disclosed |
| US-20060135503-A1 | Cyclic derivatives as modulators of chemokine receptors activity | CHERNEY ROBERT J | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135503-A1 | Cyclic derivatives as modulators of chemokine receptors activity | CCL11, CCR1, CCL2 | ALDH1A1 1022/4885TSHR 1191/4885MAPK1 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.